Investigations into Proposed Buyouts of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. and

Before you go, we thought you'd like these...
Before you go close icon

Investigations into Proposed Buyouts of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. and Maidenform Brands, Inc. Announced by Holzer Holzer & Fistel, LLC

ATLANTA--(BUSINESS WIRE)-- Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. or Maidenform Brands, Inc. common stock. The firm is investigating whether the boards of directors complied with their fiduciary duties in approving the buyouts of their respective companies. Investors who own stock in any of these companies that would like to discuss their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. (mfistel@holzerlaw.com) or Marshall P. Dees, Esq. (mdees@holzerlaw.com) via email or via toll-free telephone at (888) 508-6832.

Optimer Pharmaceuticals, Inc.


On July 30, 2013, it was announced that Cubist Pharmaceuticals would acquire all outstanding shares of Optimer Pharmaceuticals (NAS: OPTR) for $10.75 per share, plus a Contingency Value Right that would entitle the holder to an additional $5 per share if net sales targets for its drug DIFICID are achieved. The firm's investigation seeks to determine, among other things, whether the consideration to be paid to Optimer shareholders is fair and adequate.

Trius Therapeutics, Inc.

Also on July 30, 2013, Cubist Pharmaceuticals announced that it would purchase Trius Therapeutics (NAS: TSRX) common stock for $13.50 per share, with an additional Contingency Value Right of $2 per share. The firm's investigation into this proposed transaction seeks to determine if the price per share to be paid by Cubist to TSRX shareholders is fair and adequate.

Maidenform Brands, Inc.

On July 24, 2013, Maidenform Brands, Inc. (NYS: MFB) announced HanesBrands was purchasing all of its outstanding stock for $23.50 per share. The firm is investigating whether Maidenform's board of directors complied with their fiduciary duties in approving the proposed buyout.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.



Holzer Holzer & Fistel, LLC
Michael I. Fistel, Jr., Esq., 888-508-6832 (toll-free)
mfistel@holzerlaw.com
or
Marshall P. Dees, Esq., 888-508-6832 (toll-free)
mdees@holzerlaw.com

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:

The article Investigations into Proposed Buyouts of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. and Maidenform Brands, Inc. Announced by Holzer Holzer & Fistel, LLC originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners